natgillin/translations-raw huggingface dataset:
In clinical trials, smoking (which induces CYP1A2) decreased cilostazol plasma concentrations by 18%.
V kliničnih preskušanjih je kajenje (ki inducira CYP1A2) zmanjšalo koncentracije cilostazola v plazmi za 18 %.
Your doctor will assess your progress after 3 months of treatment and may recommend that you discontinue cilostazol if the effect of treatment is insufficient.
Vaš zdravnik bo po 3 mesecih zdravljenja ocenil napredek in vam lahko priporoči, da se s cilostazolom prenehate zdraviti, če učinek zdravljenja ni zadosten.
Studies in animals and in man (in vivo and ex vivo) have shown that cilostazol causes reversible inhibition of platelet aggregation.
Študije pri živalih in ljudeh man (in vivo in ex vivo) so pokazale, da cilostazol povzroča reverzibilno zaviranje agregacije trombocitov.
If you stop taking <Cilostazol-containing medicinal product> If you stop taking <Cilostazol-containing medicinal product> the pain in your legs may come back or get worse.
Če ste prenehali jemati <zdravilo, ki vsebuje cilostazol> Če ste prenehali jemati <zdravilo, ki vsebuje cilostazol>, se lahko bolečine v vaših nogah pojavijo ponovno ali poslabšajo.
The risk of intraocular bleeding may be higher in patients with diabetes.
Tveganje intraokularne krvavitve je lahko pri bolnikih s sladkorno boleznijo večje.
Cilostazol is 95-98% protein bound, predominantly to albumin.
Cilostazol se veže na beljakovine v 95-98 %, pretežno na albumin.
This leaflet was last revised in <{MM/YYYY}>.
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}.
If you feel dizzy after taking <Cilostazol-containing medicinal product> tablets, DO NOT drive and do not use any tools or machines and inform your doctor or pharmacist.
Če ste po jemanju <zdravila, ki vsebuje cilostazol>, tablete, omotični, NE vozite in ne uporabljajte orodij ali strojev ter o tem obvestite svojega zdravnika ali farmacevta.
The elderly
Starejši
Therefore, you should only stop taking <Cilostazol-containing medicinal product> if you notice side effects requiring urgent medical attention (see section 4) or if your doctor tells you to.
Zato prenehajte jemati <zdravilo, ki vsebuje cilostazol>, le takrat, če opazite neželene učinke, ki jih je treba nujno zdraviti (glejte poglavje 4), ali če vam tako naroči zdravnik.
With respect to mortality, the observed 36-month Kaplan-Meier event rate for deaths on study drug with a median time on study drug of 18 months was 5.6% (95%CI of 2.8 to 8.4%) on cilostazol and 6.8% (95% CI of 1.9 to 11.5%) on placebo.
Smrtnost glede na 36-mesečno stopnjo dogodkov po lestvici Kaplan-Meier za smrtne primere med uporabo študijskega zdravila s povprečnim časom uporabe študijskega zdravila 18 mesecev je bila 5,6 % (95-% IZ 2,8 % do 8,4 %) s cilostazolom in 6,8 % (95-% IZ 1,9 do 11,5 %) s placebom.
Approximately 30% of the dose is excreted in the urine as the 4'-trans-hydroxy metabolite.
Približno 30 % odmerka se izloči v urinu kot presnovek 4'-trans-hidroksi.
Due to the potential harmful effect in the newborn child breast fed by a treated mother, the use of <Cilostazol-containing medicinal product> is not recommended during breast feeding.
Zaradi možnih škodljivih učinkov za dojenega novorojenca matere, ki se zdravi, se uporaba <zdravila, ki vsebuje cilostazol>, med dojenjem ne priporoča.
It is important that you continue the modifications you have made to your life-style whilst taking cilostazol.
Pomembno je, da s spremenjenim slogom življenja med uporabo cilostazola nadaljujete.
If you have taken more tablets than your prescribed dose, contact your doctor or your local hospital immediately.
Če ste vzeli več tablet, kot je predpisani odmerek, se takoj posvetujte s svojim zdravnikom ali pojdite takoj v svojo lokalno bolnišnico.
You should specifically inform your doctor if you take some medicines usually used to treat painful and/or inflammatory conditions of muscle or joints, or if you take medicines to reduce blood clotting.
Svojemu zdravniku še zlasti povejte, če jemljete zdravila, ki se običajno uporabljajo za zdravljenje bolečine in/ali vnetnih stanj mišic ali sklepov, ali zdravila, ki zavirajo koagulacijo krvi.
However, some cases of pancytopenia and aplastic anaemia had a fatal outcome.
Vendar pa je bilo nekaj primerov pancitopenije in aplastične anemije s smrtnim izidom.
In addition to reporting episodes of bleeding and easy bruising, patients should be warned to promptly report any other signs which might also suggest the early development of blood dyscrasia such as pyrexia and sore throat.
Poleg poročil o epizodah krvavitev in nagnjenosti k modricam je treba bolnike opozoriti tudi, da svojemu zdravniku takoj sporočijo morebitne druge znake, ki bi lahko prav tako nakazovali na zgodnji razvoj diskrazije krvi, kot sta na primer pireksija in vnetje žrela.
The physician should reassess the patient after 3 months of treatment with a view to discontinuing cilostazol where an inadequate effect is observed or symptoms have not been improved.
Zdravnik mora bolnika po 3 mesecih zdravljenja ponovno oceniti z namenom, da preneha zdravljenje s cilostazolom, če ni opaziti ustreznega učinka ali če se simptomi ne izboljšajo.
Adverse reactions reported in clinical trials and in the post-marketing period are included in the table below.
Neželeni učinki, o katerih so poročali iz kliničnih preskušanj in obdobja trženja, so vključeni v spodnjo preglednico.
This effect appeared lower in diabetics than in non-diabetics.
Ta učinek se je zdel pri bolnikih s sladkorno boleznijo manjši kot pri tistih brez.
Exposure in late pregnancy resulted in an increased frequency of stillbirths and lower offspring weights.
Izpostavljenost v pozni brejosti je povečala pogostnost mrtvorojenih zarodkov in mladičev z nižjo telesno maso.
DO NOT take a double dose to make up for a forgotten tablet.
NE vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Patients with unstable angina pectoris, myocardial infarction within the last 6 months, or a coronary intervention in the last 6 months.
• bolniki z nestabilno angino pektoris, miokardnim infarktom v zadnjih 6 mesecih ali koronarnim posegom v zadnjih 6 mesecih
Patients with any known predisposition to bleeding (e.g. active peptic ulceration, recent [within six months] haemorrhagic stroke, proliferative diabetic retinopathy, poorly controlled hypertension)
• bolniki z znano predispozicijo za krvavitve (npr. aktivna peptična razjeda, nedavna [v zadnjih šestih mesecih] hemoragična kap, proliferativna diabetična retinopatija, slabo obvladovana hipertenzija)
Before you start taking <Cilostazol-containing medicinal product>, please inform your doctor if you are taking medicines for high blood pressure because <Cilostazol-containing medicinal product> may have an additional lowering effect on your blood pressure.
Preden začnete jemati <zdravilo, ki vsebuje cilostazol>, obvestite svojega zdravnika, če jemljete zdravila za zdravljenje visokega krvnega tlaka, saj lahko <zdravilo, ki vsebuje cilostazol>, dodatno zniža vaš krvni tlak.
In addition, an increase in foetuses with external, visceral and skeletal abnormalities was noted at high dose levels.
Poleg tega so pri visokih odmerkih opazili povečanje zarodkov z zunanjimi, visceralnimi in skeletalnimi abnormalnosti.
if you are taking both acetylsalicylic acid and clopidogrel, or any combination of two or more medicines which can increase your risk of bleeding [ask your doctor or pharmacist if you are not sure] if you have severe kidney disease or moderate or severe liver disease.
- če jemljete acetilsalicilno kislino in klopidogrel ali katero koli kombinacijo dveh ali več zdravil, ki lahko povečajo vaše tveganje za krvavitev [če niste prepričani, se posvetujte s svojim zdravnikom ali farmacevtom].
Cilostazol treatment is contraindicated in patients receiving two or more additional antiplatelet/anticoagulant agents (see section 4.3).
Zdravljenje s cilostazolom je kontraindicirano pri bolnikih, ki prejemajo dve ali več dodatnih protitrombocitnih/antikoagulacijskih zdravil (glejte poglavje 4.3).
Investigation of QTc in dogs and monkeys showed no prolongation after administration of cilostazol or its metabolites.
Preiskave QTc pri psih in opicah niso pokazale podaljšanja po dajanju cilostazola ali njegovih presnovkov.
From data generated in nine placebo-controlled studies (where 1,634 patients were exposed to cilostazol), it has been demonstrated that cilostazol improves exercise capacity as judged by changes in Absolute Claudication Distance (ACD, or maximal walking distance) and Initial Claudication Distance (ICD, or pain-free walking distance) upon treadmill testing.
Podatki, zbrani v devetih s placebom kontroliranih študijah (kjer so 1.634 bolnikov izpostavili cilostazolu), kažejo, da cilostazol izboljšuje zmožnost vadbe, kot je ocenjeno s spremembo absolutne klavdikacijske razdalje (ACD - Absolute Claudication Distance ali največje prehojene razdalje) in začetne klavdikacijske razdalje ((ICD - Initial Claudication Distance ali razdalje, prehojene brez bolečine) s testiranjem na tekočem traku.
Due to cilostazol's platelet aggregation inhibitory effect it is possible that an increased bleeding risk occurs in combination with surgery (including minor invasive measurements like tooth extraction).
Zaradi zaviralnega učinka cilostazola na agregacijo trombocitov je možno, da se bo pojavilo večje tveganje za krvavitve v kombinaciji z operacijo (vključno z manjšimi invazivnimi ukrepi, kot je ruvanje zoba).
Stop taking <Cilostazol-containing medicinal product> and contact a doctor or go to the nearest hospital immediately.
Takoj prenehajte jemati <zdravilo, ki vsebuje cilostazol>, in se nemudoma posvetujte s svojim zdravnikom ali pojdite v najbližjo bolnišnico.
However, caution is advised in patients receiving both cilostazol and any anticoagulant agent, and frequent monitoring is required to reduce the possibility of bleeding.
Vendar pa se pri bolnikih, ki prejemajo cilostazol in kateri koli drugi antikoagulant, priporoča previdnost in pogosto spremljanje, da se zmanjša možnost krvavitve.
As with other positive inotropic and vasodilator agents, cilostazol produced cardiovascular lesions in dogs.
Kot pri drugih pozitivnih inotropnih in vazodilatatorskih zdravilih, je cilostazol pri psih povzročil kardiovaskularne lezije.
Intermittent claudication is the cramp-like pain in your legs when you walk and is caused by insufficient blood supply in your legs.
Intermitentna klavdikacija je krču podobna bolečina v nogah, ki jo čutite med hojo zaradi nezadostne oskrbe nog s krvjo.
The most commonly reported adverse reactions in clinical trials were headache (in > 30%), diarrhoea and abnormal stools (in > 15% each).
Neželeni učinki, o katerih so v kliničnih preskušanjih najpogosteje poročali, so bili glavobol (pri > 30 %), driska in nenormalno blato (pri > 15 % za vsako).
<Cilostazol-containing medicinal product> is indicated for the improvement of the maximal and painfree walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II).
<Zdravilo, ki vsebuje cilostazol>, je indicirano za izboljšanje najdaljše prehojene razdalje brez bolečine pri bolnikih z intermitentno klavdikacijo, ki med mirovanjem nimajo bolečin in pri katerih ni znakov periferne nekroze tkiva (periferna arterijska bolezen stopnje II po Fontaineu).
In a single-dose clinical study, no inhibition of the metabolism of warfarin or an effect on the coagulation parameters (PT, aPTT, bleeding time) was observed.
V klinični študiji z enim odmerkom niso opazili zaviranja presnove varfarina ali učinka na koagulacijske parametre (PT, aPTT, čas krvavitve).
Effects on circulating plasma lipids have been examined in patients taking <Cilostazol-containing medicinal product>.
Učinke na lipide, ki cirkulirajo v plazmi, so ocenili pri bolnikih, ki jemljejo <zdravilo, ki vsebuje cilostazol>.
<Cilostazol-containing medicinal product> belongs to a group of medicines called phosphodiesterase type 3 inhibitors.
<Zdravilo, ki vsebuje cilostazol>, sodi v skupino zdravil, imenovana zaviralci fosfodiesteraze tipa 3.
If you are pregnant, think you may be pregnant or if you are breast-feeding ask your doctor or pharmacist for advice before taking any medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom ali farmacevtom, preden vzamete to zdravilo.
In such cases, a cilostazol dosage of 50 mg twice daily is recommended (see section 4.5 for further information).
V teh primerih se priporočajo odmerki 50 mg cilostazola dvakrat na dan (za več informacij glejte poglavje 4.5).
In total, 1,439 patients with intermittent claudication and no heart failure have been treated with cilostazol or placebo for up to three years.
Skupaj so s cilostazolom ali placebom do tri leta zdravili 1.439 bolnikov z intermitentno klavdikacijo, ki niso imeli srčnega popuščanja.
There are no data in patients with moderate or severe hepatic impairment.
Podatkov pri bolnikih z zmerno ali hudo okvaro jeter ni.
Patients who may be at increased risk for serious cardiac adverse events as a result of increased heart rate, e.g. patients with stable coronary disease, should be closely monitored during treatment with cilostazol, while the use of cilostazol in patients with unstable angina pectoris, or myocardial infarction/coronary intervention within the last 6 months, or a history of severe tachyarrhythmia is contraindicated (see section 4.3).
Bolnike, ki so lahko izpostavljeni večjemu tveganju za resne srčne neželene dogodke zaradi povišanega srčnega utripa, npr. bolnike s stabilno koronarno boleznijo, je treba med zdravljenjem s cilostazolom skrbno nadzirati, medtem ko je uporaba cilostazola pri bolnikih z nestabilno angino pektoris ali miokardnim infarktom/koronarnim posegom v zadnjih 6 mesecih ali s hudimi tahiaritmijami v anamnezi kontraindicirana (glejte poglavje 4.3).
<Cilostazol-containing medicinal product> is not suitable for children.
<Zdravilo, ki vsebuje cilostazol>, ni primerno za otroke.
There were no apparent trends toward a greater frequency of haemorrhagic adverse effects in patients taking cilostazol and ASA compared to patients taking placebo and equivalent doses of ASA.
Očitnega trenda večje pogostnosti hemoragičnih neželenih učinkov pri bolnikih, ki so jemali cilostazol in ASK, v primerjavi z bolniki, ki so jemali placebo in enakovredne odmerke ASK, ni bilo.
During treatment with <Cilostazol-containing medicinal product> make sure that
Med zdravljenjem z <zdravilom, ki vsebuje cilostazol>, se prepričajte, da
Administration of a single dose of 100 mg cilostazol with 240 ml grapefruit juice (an inhibitor of intestinal CYP3A4) did not have a notable effect on the pharmacokinetics of cilostazol.
Dajanje enega odmerka 100 mg cilostazola z 240 ml soka grenivke (zaviralec črevesnega CYP3A4) ni imelo opaznih učinkov na farmakokinetiko cilostazola.
There are no special dosage requirements for the elderly.
Za starejše bolnike ni posebnih zahtev glede odmerjanja.
If you forget to take <Cilostazol-containing medicinal product> If you miss a dose, do not worry; wait until the next dose to take your next tablet and then carry on as normal.
Če izpustite odmerek, ne skrbite; počakajte, da je čas za naslednji odmerek in vzemite naslednjo tableto, nato pa nadaljujte, kot običajno.
There are two major metabolites, a dehydro-cilostazol and a 4'-trans-hydroxy cilostazol, both of which have similar apparent half-lives.
Obstajata dva glavna presnovka, dehidrocilostazol in 4'-trans-hidroksi cilostazol, ki imata podobna navidezna razpolovna časa.
The inhibition is effective against a range of aggregants (including shear stress, arachidonic acid, collagen, ADP and adrenaline); in man the inhibition lasts for up to 12 hours, and on cessation of administration of cilostazol recovery of aggregation occurred within 48-96 hours, without rebound hyperaggregability.
Zaviranje učinkuje proti vrsti agregantov (vključno s strižno napetostjo, arahidonsko kislino, kolagenom, ADP in adrenalinom); pri ljudeh traja zaviranje do 12 ur, po prekinitvi dajanja cilostazol pa je okrevanje agregacije nastopilo v 48-96 urah, brez povratne hiperagregabilnosti.
Taking cilostazol with food has been shown to increase the maximum plasma concentrations (Cmax) of cilostazol, which may be associated with an increased frequency of adverse reactions.
Pokazalo se je, da jemanje cilostazola s hrano poveča največje koncentracije (Cmax) cilostazola v plazmi, kar je lahko povezano s povečano pogostnostjo neželenih reakcij.
If you take more <Cilostazol-containing medicinal product> than you should If for any reason you have taken more <Cilostazol-containing medicinal product> tablets than you should, you may have signs and symptoms such as severe headache, diarrhoea, a fall in blood pressure and irregularities of your heartbeat.
Če zaradi katerega koli razloga vzamete večji odmerek <zdravila, ki vsebuje cilostazol>, tablete, kot bi smeli, se bodo morda pojavili znaki in simptomi, kot so hud glavobol, driska, padec krvnega tlaka in nereden srčni utrip.
Concomitant administration of cilostazol and clopidogrel did not have any effect on platelet count, prothrombin time (PT) or activated partial thromboplastin time (aPTT).
Sočasno dajanje cilostazola in klopidogrela ni vplivalo na število trombocitov, protrombinski čas (PT) ali aktivirani delni tromboplastinski čas (aPTT).
Patients should be warned to report any episode of bleeding or easy bruising whilst on therapy.
Bolnike je treba opozoriti, da morajo sporočiti vse epizode krvavitve ali hitrega nastajanja modric med zdravljenjem.
Cilostazol may cause dizziness and patients should be warned to exercise caution before they drive or operate machinery.
Cilostazol lahko povzroči omotico, zato je treba bolnike opozoriti, da so med vožnjo ali upravljanjem s stroji previdni.
Do not use <Cilostazol-containing medicinal product> after the expiry date which is stated on the carton and blister after "EXP".
<Zdravila, ki vsebuje cilostazol>, ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnemu omotu poleg oznake "EXP".
In case of retinal bleeding administration of cilostazol should be stopped.
V primeru retinalne krvavitve je treba z uporabo cilostazola prenehati.
• If you need to have surgery including having teeth removed, tell your doctor or dentist that you are taking <Cilostazol-containing medicinal product>.
• Če vam morajo operativno odstraniti zobe, povejte svojemu zdravniku ali zobozdravniku, da jemljete <zdravilo, ki vsebuje cilostazol>.
In in vitro tests on Chinese ovary hamster cells cilostazol produced a weak but significant increase in chromosome aberration frequency.
V testih in vitro s celicami jajčnika kitajskega hrčka je cilostazol povzročil šibko, a značilno zvišanje pogostnostjo kromosomske aberacije.
If you are not sure if this applies to your medicines ask your doctor or pharmacist.
Če niste prepričani, ali kaj od tega velja za vaša zdravila, se posvetujte s svojim zdravnikom ali farmacevtom.
Your medicine is supplied in packs of 14, 20, 28, 30, 50, 56, 98, 100, 112 or 168 tablets or hospital packs with 70 (5x14) tablets.
Zdravilo je na voljo v pakiranjih po 14, 20, 28, 30, 50, 56, 98, 100, 112 ali 168 tablet ali bolnišničnih pakiranjih s 70 (5x14) tabletami.
The signs and symptoms can be anticipated to be severe headache, diarrhoea, tachycardia and possibly cardiac arrhythmias.
Pričakovani znaki in simptomi so hud glavobol, driska, tahikardija in možne srčne aritmije.
Cartons containing 14, 20, 28, 30, 50, 56, 98, 100, 112 and 168 tablets as well as hospital packs with 70 (5x14) tablets packed in PVC/Aluminium blisters.
Škatla, ki vsebuje 14, 20, 28, 30, 50, 56, 98, 100, 112 in 168 tablet ter bolnišnično pakiranje s 70 (5x14) tabletami, pakirano v pretisne omote iz PVC/aluminija.
Mutagenicity studies were negative in bacterial gene mutation, bacterial DNA repair, mammalian cell gene mutation and mouse in vivo bone marrow chromosomal aberrations.
Študije mutagenosti so bile negativne za mutacijo gena bakterije, popravljanja bakterijske DNA, genske mutacije v celicah sesalcev in kromosomske aberacije kostnega mozga pri miši in vivo.
Clopidogrel and other antiplatelet drugs
Klopidogrel in druga antiagregacijska zdravila
Animal studies have shown cilostazol to have vasodilator effects and this has been demonstrated in small studies in man where ankle blood flow was measured by strain gauge plethysmography.
Študije na živalih so pokazale, da ima cilostazol vazodilatatorski učinek, kar so ugotovili v majhnih študijah pri ljudeh, kjer so pretok krvi v gležnju izmerili s pletizmografijo z merilnimi lističi.
It has several actions which include widening of some blood vessels and reducing the clotting activity (clumping) of some blood cells called platelets inside your vessels.
Deluje na več načinov, med drugim širi nekatere krvne žile in zmanjša koagulacijo (zlepljanje) nekaterih krvnih celic, imenovanih trombociti, v vaših žilah.
Cilostazol and several of its metabolites are phosphodiesterase III inhibitors which suppress cyclic AMP degradation, resulting in increased cAMP in a variety of tissues including platelets and blood vessels.
Cilostazol in številni njegovi presnovki so zaviralci fosfodiesteraze III, ki zavira razgradnjo cikličnega AMP, kar povzroči povečanje cAMP pri različnih tkivih, vključno s trombociti in krvnimi žilami.
• Diuretics (e.g., hydrochlorothiazide, furosemide)
• diuretike (npr. hidroklorotiazid, furosemid)
Plasma concentrations (as measured by AUC) of the dehydro and 4`-trans-hydroxy metabolites are ~41% and ~12% of cilostazol concentrations.
Koncentracije v plazmi (izmerjeno z AUC) za presnovka dehidro in 4`-trans-hisdroksi sta ~41 % in ~12 % koncentracij cilostazola.
Cilostazol should be initiated by physicians experienced in the management of intermittent claudication (see also section 4.4).
Zdravljenje s cilostazolom mora uvesti zdravnik z izkušnjami pri zdravljenju intermitentne klavdikacije (glejte tudi poglavje 4.4).
• If you experience easy bruising or bleeding, stop taking <Cilostazol-containing medicinal product> and tell your doctor.
• Če hitro dobite modrice ali začnete krvaveti, prenehajte jemati <zdravilo, ki vsebuje cilostazol>, in to povejte svojemu zdravniku.
• angiotensin II receptor blockers (e.g., valsartan, candesartan)
• zaviralce receptorja angiotenzina II (npr. valsartan, kandesartan)
Patients with any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, whether or not adequately treated, and in patients with prolongation of the QTc interval
• bolniki z ventrikularno tahikardijo, ventrikularno fibrilacijo ali multifokalno ventrikularno ektopijo v anamnezi, z ustreznim zdravljenjem ali brez njega, in bolniki s podaljšanim intervalom QTc
In subjects with severe renal impairment, the free fraction of cilostazol was 27% higher and both Cmax and AUC were 29% and 39% lower respectively than in subjects with normal renal function.
Pri osebah s hudo okvaro delovanja ledvic je bila prosta frakcija cilostazola 27 % višja, Cmax in AUC pa sta bila 29 % oz. 39 % nižja kot pri osebah z normalnim delovanjem ledvic.
You have been prescribed <Cilostazol-containing medicinal product> for "intermittent claudication".
<Zdravilo, ki vsebuje cilostazol>, vam je bilo predpisano za "intermitentno klavdikacijo".
• acetylsalicylic acid
• acetilsalicilno kislino
Patients receiving treatment with cilostazol should continue with their life-style modifications (smoking cessation and exercise), and pharmacological interventions (such as lipid lowering and antiplatelet treatment) to reduce the risk of cardiovascular events.
Bolniki, ki se zdravijo s cilostazolom, naj spremembe svojega življenjskega sloga izvajajo še naprej (prenehanje kajenja in vadba) in nadaljujejo s farmakološkimi ukrepi (kot je zdravljenje z zdravili za zmanjšanje maščob in z protitrombocitnimi zdravili), da zmanjšajo tveganje za nastanek kardiovaskularnih dogodkov.